Brocabe

Bruton’s tyrosine kinase inhibitor, oral antineoplastic. Indicated for the treatment of oncohematologic neoplasms (chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma), Waldenström’s macroglobulinemia, and graft-versus-host disease.

Therapeutic Area
Oncohematology

Active Ingredient
Ibrutinib

Line
Oncology

Dosage forms
140 mg x 90 hard capsules and 120 hard capsules